Incidence of Treatment for End-stage Renal Disease Among Individuals with Diabetes in the U.S. Continues to Decline

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2009 Dec 31

PMID 20040673

Citations 67

Authors

Nilka Rios Burrows

Yanfeng Li

Linda S Geiss

Affiliations

Soon will be listed here.

Abstract

Objective: We examined trends in incidence of treatment for diabetes-related end-stage renal disease (ESRD) in the U.S.

Research Design And Methods: Using the U.S. Renal Data System, we obtained the number of individuals having diabetes listed as primary diagnosis who initiated ESRD treatment between 1990 and 2006. Incidence was calculated using the estimated U.S. population with diabetes from the National Health Interview Survey and then was age adjusted based on the 2000 U.S. standard population. Trends were analyzed using joinpoint regression.

Results: The number of individuals who began diabetes-related ESRD treatment increased from 17,727 in 1990 to 48,215 in 2006. From 1990 to 1996, the age-adjusted diabetes-related ESRD incidence increased somewhat from 299.0 to 343.2 per 100,000 diabetic population (P = 0.45). However, from 1996 to 2006, the age-adjusted diabetes-related ESRD incidence decreased by 3.9% per year (P < 0.01) from 343.2 to 197.7 per 100,000 diabetic population. Among individuals with diabetes aged <45 years, diabetes-related ESRD incidence decreased by 4.3% per year (P < 0.01) from 1990 to 2006. Among older individuals, incidence increased during the 1990s but decreased in later years, by 3.9% per year (P < 0.01) among individuals aged 45-64, by 3.4% per year (P < 0.01) among individuals aged 65-74 years, and by 2.1% per year (P = 0.02) among individuals aged > or =75 years.

Conclusions: Diabetes-related ESRD incidence in the diabetic population has declined in all age-groups, probably because of a reduction in the prevalence of ESRD risk factors, improved treatment and care, and other factors.

Citing Articles

The advance of single cell transcriptome to study kidney immune cells in diabetic kidney disease.

Wang M, Yao F, Chen N, Wu T, Yan J, Du L BMC Nephrol. 2024; 25(1):412.

PMID: 39550562 PMC: 11568691. DOI: 10.1186/s12882-024-03853-y.

The problem of pulmonary arterial hypertension in end-stage renal disease: can peritoneal dialysis be the solution.

Alhwiesh A, Abdul-Rahman I, Alshehri A, Alhwiesh A, Elnokeety M, Essam S BMC Nephrol. 2022; 23(1):386.

PMID: 36471276 PMC: 9721065. DOI: 10.1186/s12882-022-02998-y.

Galectin-1 in Obesity and Type 2 Diabetes.

Fryk E, Silva V, Jansson P Metabolites. 2022; 12(10).

PMID: 36295832 PMC: 9606923. DOI: 10.3390/metabo12100930.

Sarcopenia Is an Independent Risk Factor for Severe Diabetic Nephropathy in Type 2 Diabetes: A Long-Term Follow-Up Propensity Score-Matched Diabetes Cohort Study.

Huang Y, Chen W, Chen M, Shia B, Wu S J Clin Med. 2022; 11(11).

PMID: 35683381 PMC: 9181390. DOI: 10.3390/jcm11112992.

Obesity and Chronic Kidney Disease in US Adults With Type 1 and Type 2 Diabetes Mellitus.

Wallace A, Chang A, Shin J, Reider J, Echouffo-Tcheugui J, Grams M J Clin Endocrinol Metab. 2022; 107(5):1247-1256.

PMID: 35080610 PMC: 9016431. DOI: 10.1210/clinem/dgab927.

References

Imperatore G, Cadwell B, Geiss L, Saadinne J, Williams D, Ford E . Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. Am J Epidemiol. 2004; 160(6):531-9. DOI: 10.1093/aje/kwh232. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Saaddine J, Cadwell B, Gregg E, Engelgau M, Vinicor F, Imperatore G . Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006; 144(7):465-74. DOI: 10.7326/0003-4819-144-7-200604040-00005. View

Hsu C, Lin F, Vittinghoff E, Shlipak M . Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003; 14(11):2902-7. DOI: 10.1097/01.asn.0000091586.46532.b4. View

. Incidence of end-stage renal disease among persons with diabetes--United States, 1990-2002. MMWR Morb Mortal Wkly Rep. 2005; 54(43):1097-100. View

Cheung B, Ong K, Cherny S, Sham P, Tso A, Lam K . Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009; 122(5):443-53. DOI: 10.1016/j.amjmed.2008.09.047. View

Ong K, Cheung B, Wong L, Wat N, Tan K, Lam K . Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol. 2008; 18(3):222-9. DOI: 10.1016/j.annepidem.2007.10.007. View

Parving H, Hovind P . Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep. 2002; 4(5):387-93. DOI: 10.1007/s11906-002-0069-3. View

Plantinga L, Boulware L, Coresh J, Stevens L, Miller 3rd E, Saran R . Patient awareness of chronic kidney disease: trends and predictors. Arch Intern Med. 2008; 168(20):2268-75. PMC: 2652122. DOI: 10.1001/archinte.168.20.2268. View

10.

. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160):703-13. PMC: 28659. View

11.

Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

12.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

13.

Kim H, Fay M, Feuer E, Midthune D . Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19(3):335-51. DOI: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z. View

14.

. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20(7):1183-97. DOI: 10.2337/diacare.20.7.1183. View